Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase – Should You Buy?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares saw unusually-high trading volume on Thursday . Approximately 105,365 shares traded hands during trading, an increase of 247% from the previous session’s volume of 30,375 shares.The stock last traded at $7.78 and had previously closed at $7.21.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday.

Aligos Therapeutics Trading Down 7.0 %

The firm has a market cap of $656.12 million, a price-to-earnings ratio of -6.56 and a beta of 2.16. The stock’s 50 day moving average is $10.59 and its 200 day moving average is $13.53.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same quarter last year, the company posted ($10.75) EPS. On average, equities research analysts predict that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently bought and sold shares of ALGS. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after purchasing an additional 171,490 shares during the period. Opaleye Management Inc. boosted its holdings in Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares during the period. Finally, Armistice Capital LLC boosted its holdings in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the period. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).